Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback